Colony Stimulating Factor-1 Receptor Blocker class drugs

1 result
Incyte Corporation
Usage: NIKTIMVO is indicated for treating chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, after they have failed at least two prior lines of systemic therapy.